# MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL

> **NCT06367374** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 66 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Sonrotoclax
- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT06367374
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05-30
- **Primary completion:** 2030-02-28
- **Final completion:** 2030-07-30
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2024-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06367374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06367374, "MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT06367374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*